SCHEMBL4391357

SCHEMBL4391357

Cc1nc(-c2ccnc(Nc3cccc(N)c3)n2)sc1C

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDK2 P24941 13/20 0.68
CDK4 P11802 9/20 0.68
SRC P12931 5/20 0.59
ABL1 P00519 3/20 0.59
BCR P11274 2/20 0.59
EGFR P00533 1/20 0.57
PRKACA P17612 1/20 0.57
PRKACG P22612 1/20 0.57
PRKACB P22694 1/20 0.57
CDK5 Q00535 3/20 0.57
ZAP70 P43403 3/20 0.53
SYK P43405 3/20 0.53
CAMK2D Q13557 1/20 0.53
CDK1 P06493 4/20 0.52
CDK7 P50613 4/20 0.52
CDK9 P50750 4/20 0.52
CCNT1 O60563 3/20 0.52
CCNB1 P14635 3/20 0.52
CCNA2 P20248 3/20 0.52
CCNH P51946 3/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14216067 0.86 SRC (0.72) CDK2CDK4SRCABL1BCR
SCHEMBL4388095 0.86 CDK2 (0.68) CDK2CDK4SRCZAP70SYK
SCHEMBL14378999 0.85 CDK2 (0.64) CDK2CDK4SRCABL1EGFR
SCHEMBL14008738 0.84 CDK2 (0.51) CDK2CDK4SRCABL1BCR
SCHEMBL14216016 0.84 ZAP70 (0.72) CDK2CDK4SRCZAP70SYK
SCHEMBL4385809 0.83 AURKA (0.58) CDK2CDK4SRCZAP70SYK
SCHEMBL4386032 0.82 CDK2 (0.72) CDK2CDK4SRCABL1BCR
SCHEMBL6157725 0.81 CDK2 (0.83) CDK2CDK4SRCABL1BCR
SCHEMBL6159771 0.81 CDK2 (1.00) CDK2CDK4SRCABL1BCR
SCHEMBL13589139 0.79 CDK2 (0.49) CDK2CDK4SRCZAP70SYK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1751146-B1 PYRIDINYL- OR PYRIMIDINYL THIAZOLES WITH PROTEIN KINASE INHIBITING ACTIVITY CYCLACEL LTD (GB) 2009-12-02 EP claimed
US-20080318954-A1 Compounds CYCLACEL LIMITED (GB) 2008-12-25 US claimed
EP-1751146-B1 PYRIDINYL- OR PYRIMIDINYL THIAZOLES WITH PROTEIN KINASE INHIBITING ACTIVITY CYCLACEL LTD (GB) 2009-12-02 EP disclosed
EP-1751146-B1 PYRIDINYL- OR PYRIMIDINYL THIAZOLES WITH PROTEIN KINASE INHIBITING ACTIVITY CYCLACEL LTD (GB) 2009-12-02 EP disclosed
US-20080318954-A1 Compounds CYCLACEL LIMITED (GB) 2008-12-25 US disclosed
US-20080318954-A1 Compounds CYCLACEL LIMITED (GB) 2008-12-25 US disclosed
US-20080318954-A1 Compounds CYCLACEL LIMITED (GB) 2008-12-25 US disclosed
EP-1751146-A2 PYRIDINYL- OR PYRIMIDINYL THIAZOLES WITH PROTEIN KINASE INHIBITING ACTIVITY Cyclacel Limited (GB) 2007-02-14 EP disclosed
WO-2005075468-A2 PYRIDINYL - OR PYRIMIDINYL THIAZOLES WITH PROTEIN KINASE INHIBITING ACTIVITY CYCLACEL LIMITED (GB) 2005-08-18 WO disclosed
WO-2005075468-A2 PYRIDINYL - OR PYRIMIDINYL THIAZOLES WITH PROTEIN KINASE INHIBITING ACTIVITY CYCLACEL LIMITED (GB) 2005-08-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080318954-A1 Compounds CBR3, NR3C2, NR5A1 CDK2 1186/4885CDK4 607/4885SRC 1992/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.